Research Article
LipoxinA4 as a Potential Prognostic Marker of COVID-19

Farzaneh Jamali,1 Bita Shahrami,1 Amirmahdi Mojtabahzedeh,2 Farhad Najmeddin,1 Amir Ahmad Arabzadeh,3 Azar Hadadi,4 Mohammad Sharifzadeh,5 and Mojtaba Mojtabahzedeh1

1Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2Semmelweis University, Faculty of Medicine, Budapest, Hungary
3Department of Surgery, Faculty of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
4Department of Infectious Disease, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5Department of Toxicology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Mojtaba Mojtabahzedeh; mojtahed@sina.tums.ac.ir

Received 5 April 2022; Revised 2 June 2022; Accepted 14 June 2022; Published 5 July 2022

Academic Editor: Rhoderick Brown

Copyright © 2022 Farzaneh Jamali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This pilot study aimed to determine early changes of LXA4 levels among the hospitalized patients confirmed as COVID-19 cases following the clinical management and its correlation with commonly used inflammatory markers, including erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and ferritin. Thirty-one adult hospitalized patients infected with the non-severe COVID-19 were included. LXA4 levels were measured at the baseline and 48-72 hours after hospitalization. Accordingly, ESR and CRP levels were collected on the first day of hospitalization. Moreover, the maximum serum ferritin levels were determined during the five days. LXA4 levels significantly increased at 48-72 hours compared to the baseline. ESR, CRP, and ferritin levels were positively correlated with the increased LXA4. In contrast, aging was shown to negatively correlate with the increased LXA4 levels. LXA4 may be known as a valuable marker to assess the treatment response among non-elderly patients with non-severe COVID-19. Furthermore, LXA4 could be considered as a potential treatment option under inflammatory conditions. Further studies are necessary to clarify LXA4 role in COVID-19 pathogenesis, as well as the balance between such pro-resolving mediators and inflammatory parameters.

1. Introduction

Inflammation is an active process associated with the anti-inflammatory mediators’ production [1]. These mediators, called specialized pro-resolving mediators (SPMs), are a group of bioactive lipids (BALs). Lipoxins (LXs), are a member of SPMs, involved in the active phase of the resolution, which is thought to control inflammation, promote healing, and limit tissue damage [2]. It is believed that a complex correlation exists between inflammatory and non-inflammatory mediators in several inflammatory and infectious diseases, including coronavirus disease 2019 (COVID-19) [3–5].

2. Materials and Methods

An observational pilot study was performed on adult patients hospitalized due to non-severe COVID-19. Serum LXA4 levels were measured once at the time of admission and once 48-72 hours later by human ELISA kit in every patient. The assay range of the ELISA kit was from 75 to 2400 ng/L, and the sensitivity was measured as 9.5 ng/L. Therefore, LXA4 levels below the detection value (<9.5 ng/L) were considered as 9.5 ng/L for the statistical analysis. Baseline erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP) levels and the maximum ferritin level during the five days of hospitalization were also measured.
3. Results

The data obtained from a total of 31 patients were analyzed. The mean (±SD) age of the patients, was 61.9 ± 17 years old.

Changes of LXA₄ levels by age are shown in Figure 1. LXA₄ concentrations significantly increased after early interventions in the hospital (P < 0.05). In addition, there was an inverse correlation between age and changes in LXA₄, indicating that LXA₄ levels less increased with aging (R = -0.375; P = 0.037).

The mean ±SD baseline concentrations of ESR, and CRP as well as the maximum concentration of ferritin were 55.7 ± 33.7 mm/h, 74.7 ± 57.3 mg/L, and 568.7 ± 530.0 ng/mL, respectively. The results show that the patients with higher serum ESR and CRP levels at the time of admission also had a greater increase in LXA₄ concentration (R = 0.535, 0.499; P = 0.005, 0.007, respectively). The positive correlation between the maximum ferritin levels and the LXA₄ changes was statistically significant as well (R = 0.398; P = 0.043).

4. Discussion

LXs are anti-inflammatory mediators that increase at early stages of resolution [6]. Despite conducting extensive research on the pro-inflammatory mediators, the pro-resolving roles in COVID-19 have been poorly studied. This pilot study showed that LXA₄ levels increased in the hospitalized patients with non-severe COVID-19 following performing the early therapeutic interventions.

Yang et al. in their study [7] showed that LXs and other SPMs have protective effects in pulmonary diseases associated with inflammation. Additional studies [8, 9] have shown a significant correlation between chronic obstructive pulmonary disease (COPD), severe asthma, and low levels of LXA₄ [10]. SPMs have shown positive effects on treating sepsis, improving survival, and reducing the need for antibiotics as well [11].

There are studies demonstrating that when human cells are exposed to SARS-CoV-2, they secrete large amounts of BALs [12, 13]. Archambault et al. [14] reported that LXA₄ is detectable in the bronchoalveolar lavage fluid (BALF) of severe COVID-19 patients. In addition, the levels of SPMs and pro-inflammatory lipids were simultaneously high, indicating the coexistence of such mediators in the acute phase of inflammation, while the resolution process was not fully engaged. LXA₄ was indicated to have a significant correlation with prostaglandin E₂, prostaglandin D₂, and thromboxane B₂, but it had no significant correlation with clinical parameters and aging. In the present study, in contrast, the changes of LXA₄ were observed to be correlated with ESR, CRP, and ferritin indicating that the patients with higher inflammatory states secreted more LXA₄. Another finding of this study was the significant inverse correlation between aging and changes in LXA₄ concentration. The effects of aging factors on COVID-19 have been previously investigated [15–17]. The baseline inflammation predisposes the elderly to hyper-inflammatory response and impaired resolution [18] which is consistent with our results.

The present study suggests that along with the inflammatory response to pathogens, active resolution, and the timely conversion to resolution phase are of great importance in having an effective fight on the coronavirus. Therefore, SPMs without any immunosuppressive effect may be potential treatment options under inflammatory conditions. Besides, early changes of LXA₄ in our study showed that such mediators might be valuable markers for assessing the treatment response compared to common-used inflammatory markers with fewer changes. However, the LXA₄
use is not recommended in the elderly population because of undetectable low levels.

5. Conclusion

LXA₄ is suggested to be a beneficial biomarker in infectious and inflammatory diseases like COVID-19.

Data Availability

All data generated or analyzed during this study are included in this published article.

Disclosure

The research was previously presented as an abstract at the 6th international conference on prevention and infection control (ICPIC 2021). The manuscript has been presented as a preprint [19].

Conflicts of Interest

The authors declare that they have no known competing interests that could have appeared to influence the work reported in this paper.

Acknowledgments

This work was supported by the Tehran University of Medical Sciences.

References

[1] C. N. Serhan, “Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms,” The FASEB Journal, vol. 31, no. 4, pp. 1273–1288, 2017.
[2] J. A. Chandrasekharan and N. Sharma-Walia, “Lipoxins: nature’s way to resolve inflammation,” Journal of Inflammation Research, vol. 8, article 181, 2015.
[3] M. A. Sugimoto, L. P. Sousa, V. Pinho, M. Perretti, and M. M. Teixeira, “Resolution of inflammation: what controls its onset?,” Frontiers in Immunology, vol. 7, p. 160, 2016.
[4] A. Sadremomtaz, J. Hashemi, A. Sahebnasagh et al., “A possible guide as a tool to complementary effects of new coronavirus,” Archives of Anesthesiology and Critical Care, vol. 7, no. 4, pp. 253–277, 2021.
[5] S. Gheibi, F. Najmeddin, B. Shahrami, K. Sadeghi, and M. Mojtabahzadeh, “The controversies surrounding tocilizumab administration following pathogen-associated molecular pattern (PAMP) induced by COVID-19,” Journal of Pharmaceutical Care, vol. 8, no. 3, pp. 140–142, 2020.
[6] C. H. Lee, “Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm,” Archives of Pharmacal Research, vol. 44, no. 1, pp. 84–98, 2021.
[7] A. Yang, Y. Wu, G. Yu, and H. Wang, “Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development,” Respiratory Research, vol. 22, pp. 1–17, 2021.
[8] C. Barnig, M. Cernadas, S. Dutile et al., “Lipoxin A₄Regulates natural killer cell and type 2 innate lymphoid cell activation in asthma,” Science Translational Medicine, vol. 5, no. 174, pp. 174ra26–174ra26, 2013.
[9] S. Kazani, A. Planaguma, E. Ono et al., “Exhaled breath condensate eicosanoid levels associate with asthma and its severity,” Journal of Allergy and Clinical Immunology, vol. 132, no. 3, pp. 547–553, 2013.
[10] M. Bukovskis, M. Beinare, V. Garduşina, and I. Taivāns, “Lipoxigenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease,” Medicina (Kaunas, Lithuania), vol. 48, no. 6, pp. 43–48, 2012.
[11] T. Ueda, K. Fukunaga, H. Seki et al., “Combination therapy of 15-epi-Lipoxin A₄ with antibiotics protects mice from Escherichia coli–induced sepsis,” Critical Care Medicine, vol. 42, no. 4, pp. e288–e295, 2014.
[12] B. Yan, H. Chu, D. Yang et al., “Characterization of the lipidomic profile of human coronavirus-infected cells: implications for lipid metabolism remodeling upon coronavirus replication,” Viruses, vol. 11, no. 1, p. 73, 2019.
[13] U. N. Das, “Bioactive lipids in COVID-19--further evidence,” Archives of Medical Research, vol. 52, no. 1, pp. 107–120, 2021.
[14] A. S. Archambault, Y. Zaid, V. Rakotoarivelo et al., “Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxigenase-derived inflammatory metabolites,” MedRxiv, 2020.
[15] L. S. Nidadavolu and J. D. Walston, “Underlying vulnerabilities to the cytokine storm and adverse COVID-19 outcomes in the aging immune system,” The Journals of Gerontology: Series A, vol. 76, no. 3, pp. e13–e18, 2021.
[16] S. Salimi and J. M. Hamlyn, “COVID-19 and crosstalk with the hallmarks of aging,” The Journals of Gerontology: Series A, vol. 75, no. 9, pp. e34–e41, 2020.
[17] F. Perrotta, G. Corbi, G. Mazzeo et al., “COVID-19 and the elderly: insights into pathogenesis and clinical decision-making,” Aging Clinical and Experimental Research, vol. 32, no. 8, pp. 1599–1608, 2020.
[18] A. N. Akbar and D. W. Gilroy, “Aging immunity may exacerbate COVID-19,” Science, vol. 369, no. 6501, pp. 256-257, 2020.
[19] F. Jamali, B. Shahrami, F. Najmeddin et al., “Changes of lipoxin4 levels following early hospital management of patients with COVID-19,” Antimicrobial Resistance and Infection Control, vol. 10, no. Supplement 1, 2021.